Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04581343
Title A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients (PanCAN-SR1)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Pancreatic Cancer Action Network

pancreatic adenosquamous carcinoma

pancreatic ductal adenocarcinoma


Canakinumab + Gemcitabine + Nab-paclitaxel + Spartalizumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.